Jpmorgan Chase & CO Entera Bio Ltd. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Entera Bio Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2 shares of ENTX stock, worth $4. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2Holding current value
$4% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ENTX
# of Institutions
21Shares Held
5.34MCall Options Held
2.6KPut Options Held
100-
Knoll Capital Management, LLC Miami, FL3.88MShares$8.77 Million3.64% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY649KShares$1.47 Million0.01% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT411KShares$929,0310.11% of portfolio
-
Ubs Group Ag143KShares$322,6080.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny61.2KShares$138,3120.0% of portfolio
About Entera Bio Ltd.
- Ticker ENTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,809,900
- Market Cap $65.1M
- Description
- Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...